Table 1.
Patient characteristics.
| Patient | Sex | Diagnosis (Dx) | Age at Dx (y) | Stage at Dx | Age at Sample Collection | TTI-621 Clinical Trial | TNMB at Enrollment | Studies Performed |
Prior Treatment(s) |
|---|---|---|---|---|---|---|---|---|---|
| MF01 | F | MF | 62 | IB | 70 | Yes | T3N0M0B0 | MSI, scRNA-seq * | bexarotene, NB-UVB, IFN, LEBT, ECP, brentuximab vedotin |
| MF02 | M | MF | 66 | IIB | 68 | Yes | T3N0M0B0 | MSI | LEBT |
| MF03 | F | MF | 42 | IA | 64 | Yes | T2bN0M0B0 | MSI | ECP, chlormethine, PUVA, bexarotene, MTX, pralatrexate, romidepsin |
| MF04 | F | MF | 39 | IVA1 | 63 | Yes | T3N1M0B0 | MSI | ECP, IFN, allogeneic HSCT, LEBT, brentuximab vedotin, vbortezomib |
| MF05 | M | MF | 60 | IB | 63 | Yes | T3N1M0B0 | MSI | bexarotene, IFN |
| MF06 | M | MF | 59 | IA | 72 | Yes | T3N0M0B0 | MSI | LEBT, NB-UVB, bexarotene, IFN, chlormethine, pralatrexate |
| MF07 | M | MF | 52 | IIB | 61 | Yes | T1bN0M0B0 | MSI, scRNA-seq * | LEBT, MTX, bexarotene, chlormethine |
| MF08 | M | MF | 72 | IB | 72 | Yes | T1bN0M0B0 | MSI | None |
| MF09 | F | MF | 66 | IIB | 72 | No | - | scRNA-seq | chlormethine, IFN, bexarotene, brentuximab vedotin, romidepsin, pralatrexate |
| MF10 | F | MF | 83 | IIB | 83 | No | - | scRNA-seq | NB-UVB, pralatrexate |
* scRNA-seq samples were collected prior to enrollment in the TTI-621 clinical trial. IFN = pegylated interferon alfa-2a. LEBT = low-dose electron beam radiation. ECP = extracorporeal photophoresis. MTX = methotrexate. HSCT = hematopoietic stem cell transplant.